• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

    8/5/21 6:07:39 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVS alert in real time by email
    HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously
    Get the next $CLVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVS

    DatePrice TargetRatingAnalyst
    5/6/2022Buy → Neutral
    H.C. Wainwright
    9/21/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    8/5/2021$12.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

      Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the "Debtors") have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell their assets through a court supervised sales process. The Debtors have filed various "first day" motions with the Bankruptcy Court request

      12/12/22 12:18:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

      Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, "TRITON3: A Phase 3 Study of Rucaparib vs. Physician's Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)" is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, "Novel Clinical Trial Updates" at the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat. The presentation is available at https

      10/27/22 5:05:00 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

      Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose No serious adverse events, treatment discontinuations, or deaths related to 177Lu-FAP-2286 observed Confirmed partial response (PR) in one patient who completed the maximum six administrations of 177Lu-FAP-2286 in the 3.7 GBq dose cohort Patient continues without disease progression or subsequent anti-cancer therapy more than twelve months after first dose Stable disease (SD) in one heavily pretreated patient who completed four administrations of 177Lu-FAP-2286 in the 5.55 GBq dose coho

      10/17/22 3:45:00 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clovis Oncology downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Clovis Oncology from Buy to Neutral

      5/6/22 11:33:29 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      9/21/21 6:26:42 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      8/5/21 6:07:39 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      12/22/22 4:37:40 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

      Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-11) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 06/10/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

      6/13/22 2:20:18 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care